Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

86
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
86
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

1.3K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
1.3K
Autoimmune Disorders01:29

Autoimmune Disorders

409
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
409
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

312
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
312
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

507
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
507
Liver Physiology01:30

Liver Physiology

502
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of  70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
502

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Baseline and Longitudinal Liver Stiffness Measurement Predict Outcomes in Primary Biliary Cholangitis: A Multicenter Study.

Hepatology research : the official journal of the Japan Society of Hepatology·2026
Same author

CLEIA-based type IV collagen 7S for second-step assessment of MRE-defined clinically significant fibrosis in MASLD with indeterminate FIB-4.

Scientific reports·2026
Same author

Borderline Resectable Classification Identifies Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab.

Hepatology research : the official journal of the Japan Society of Hepatology·2026
Same author

Gastric peroral endoscopic myo-neurotomy as less-invasive bariatric surgery in porcine models: an experimental study.

iGIE : innovation, investigation and insights·2026
Same author

Efficacy and Safety of a Revised Gastric Peroral Endoscopic Myo-Neurotomy Procedure for Bariatric Endoscopy in a Porcine Model.

DEN open·2026
Same author

Nationwide comprehensive genomic profiling defines the genomic landscape of hepatocellular carcinoma across etiologies.

Scientific reports·2025

Related Experiment Video

Updated: Jun 22, 2025

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.0K

Autoimmune Hepatitis with Metabolic Dysfunction-associated Fatty Liver Disease.

Atsushi Takahashi1, Hiromasa Ohira1, Kazumichi Abe1

  • 1Department of Gastroenterology, Fukushima Medical University School of Medicine, Japan.

Internal Medicine (Tokyo, Japan)
|July 3, 2024
PubMed
Summary

Metabolic-associated fatty liver disease (MAFLD) impacts autoimmune hepatitis (AIH) patients differently. MAFLD patients show distinct clinical traits and higher liver enzyme levels post-treatment, aiding understanding of this dual diagnosis.

Keywords:
autoimmune hepatitis (AIH)metabolic-associated fatty liver disease (MAFLD)nationwide survey

More Related Videos

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

7.0K
Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.1K

Related Experiment Videos

Last Updated: Jun 22, 2025

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.0K
An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

7.0K
Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.1K

Area of Science:

  • Hepatology
  • Internal Medicine
  • Gastroenterology

Background:

  • Metabolic-associated fatty liver disease (MAFLD) is a recently proposed entity.
  • Characteristics of patients with co-existing autoimmune hepatitis (AIH) and MAFLD are not well understood.
  • Clarifying these characteristics is crucial for effective patient management.

Purpose of the Study:

  • To evaluate the clinical characteristics of patients with autoimmune hepatitis (AIH) and co-existing metabolic-associated fatty liver disease (MAFLD).
  • To compare patients with AIH and MAFLD against those with AIH alone.

Main Methods:

  • Re-analysis of the 2018 Japanese Nationwide Survey of AIH.
  • Inclusion of patients diagnosed with AIH between 2014 and 2017.
  • Categorization of AIH patients based on the presence or absence of MAFLD for comparative analysis.

Main Results:

  • Prevalence of MAFLD among AIH patients was 10.5% (45 out of 427 patients).
  • AIH patients with MAFLD exhibited higher BMI, increased hypertension rates, milder initial liver enzyme/bilirubin elevation, and more advanced fibrosis.
  • Post-treatment, AIH patients with MAFLD showed significantly higher hepatobiliary enzyme and total bilirubin levels compared to those without MAFLD.

Conclusions:

  • AIH patients with MAFLD present distinct clinical and biochemical profiles compared to AIH patients without MAFLD.
  • These findings contribute to a better understanding of the interplay between AIH and MAFLD.
  • Further research into managing this specific patient cohort is warranted.